Biotech Values

[jq1234]

MRK 2-DAA FDC: The first trial is for patient who "Has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease". MRK has a similarly designed trial already without excluding these patients specifically:

http://clinicaltrials.gov/ct2/show/NCT02105467?term=Mk5172&phase=2&rank=10

The question is why they need another trial for sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease specifically? I don't remember either GILD or ABBV specifically included/excluded these patients in their trials.